CIK 0000886163 · Large accelerated filer
LIGAND PHARMACEUTICALS INC
Sign in to watch- Tickers
- LGND LGNDZ LGNXZ LGNYZ LGNZZ
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 770160744
- Phone
- 858-550-7500
- Business address
- 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO, CA, 92121
- Former names
- LIGAND PHARMACEUTICALS
Securities
- LGND Common Stock Nasdaq
- LGNDZ Common stock OTC
- LGNXZ Common stock OTC
- LGNYZ Common stock OTC
- LGNZZ Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $6,585,411
- in 7 filings, $4.5M under 10b5-1 plans
Net −$6,585,411. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-03 | Reardon Andrew CLO & Secretary | Sale 10b5-1 | −2,115 | $286.36 | $606K | 37,299 |
| 2026-09-03 | Reardon Andrew CLO & Secretary | Sale 10b5-1 | −385 | $287.53 | $111K | 36,914 |
| 2026-09-03 | Reardon Andrew CLO & Secretary | Sale 10b5-1 | −400 | $288.98 | $116K | 36,514 |
| 2026-08-12 | Espinoza Octavio Chief Financial Officer | Option exercise 10b5-1 | +16,179 | $52.84 | $855K | 43,875 |
| 2026-08-12 | Espinoza Octavio Chief Financial Officer | Option exercise 10b5-1 | +2,074 | $70.04 | $145K | 45,949 |
| 2026-08-12 | Espinoza Octavio Chief Financial Officer | Option exercise 10b5-1 | +2,869 | $55.75 | $160K | 48,818 |
| 2026-08-12 | Espinoza Octavio Chief Financial Officer | Option exercise 10b5-1 | +7,171 | $57.22 | $410K | 55,989 |
| 2026-08-12 | Espinoza Octavio Chief Financial Officer | Option exercise 10b5-1 | +3,348 | $68.74 | $230K | 59,337 |
| 2026-08-12 | Espinoza Octavio Chief Financial Officer | Sale 10b5-1 | −31,641 | $292.07 | $9.2M | 27,696 |
| 2026-08-12 | Espinoza Octavio Chief Financial Officer | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −2,869 | 0 | ||
| 2026-08-12 | Espinoza Octavio Chief Financial Officer | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −7,171 | 0 | ||
| 2026-08-12 | Espinoza Octavio Chief Financial Officer | Option exercise · Non-Qualified Stock Option (right to buy) 10b5-1 | −16,179 | 0 | ||
| 2026-08-12 | Espinoza Octavio Chief Financial Officer | Option exercise · Non-Qualified Stock Option (right to buy) 10b5-1 | −3,348 | 0 | ||
| 2026-08-12 | Espinoza Octavio Chief Financial Officer | Option exercise · Non-Qualified Stock Option (right to buy) 10b5-1 | −2,074 | 0 | ||
| 2026-08-12 | Haas Jason Director | Option exercise | +6,138 | $51.56 | $316K | 11,119 |
| 2026-08-12 | Haas Jason Director | Sale | −7,138 | $292.81 | $2.1M | 3,981 |
| 2026-08-12 | Haas Jason Director | Option exercise · Non-Qualified Stock Option (right to buy) | −6,138 | 0 | ||
| 2026-08-03 | Reardon Andrew CLO & Secretary | Option exercise 10b5-1 | +5,000 | $52.27 | $261K | 46,514 |
| 2026-08-03 | Reardon Andrew CLO & Secretary | Sale 10b5-1 | −105 | $284.14 | $30K | 46,409 |
| 2026-08-03 | Reardon Andrew CLO & Secretary | Sale 10b5-1 | −33 | $284.55 | $9K | 46,376 |
Page 3 of 43 · 858 trades